zoledronic acid has been researched along with Carcinoma, Epidermoid in 18 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (16.67) | 29.6817 |
2010's | 14 (77.78) | 24.3611 |
2020's | 1 (5.56) | 2.80 |
Authors | Studies |
---|---|
Billhymer, A; Lundberg, AP; Selting, KA; Tran Hoang, C | 1 |
Colak, U; Hatun, S; Kayserili, H; Mutlu, GY; Sozmen, BO; Yucel, EB | 1 |
López Jornet, P; Pons-Fuster López, E; Wang, QT; Wei, W | 1 |
Arai, N; Kurohara, K; Kutsuna, T; Murata, T; Shimizu, K; Tomeoku, A | 1 |
Domae, E; Goda, S; Hirai, Y; Ikeo, T; Tsuji, K | 1 |
Kumar, G; Kumar, N; Sundriyal, D; Walia, M | 1 |
Draenert, FG; Heymann, PG; Kämmerer, PW; Kretschmer, F; Mandic, R; Neff, A; Saydali, A | 1 |
Alvaro, PF; Lopez Jornet, P; Rosario, TM; Susana, SC | 1 |
Bezaury, AP; Nevarez-Barragan, MJ; Perez-Diaz, I; Rosas-Jurado, MG; Trejo-Rosales, R | 1 |
Arai, N; Hattori, Y; Inoue, S; Noguchi, M; Takashina, M; Tomihara, K | 1 |
Bertolini, F; Codeluppi, M; Conte, PF; De Matteis, E; Frassoldati, A; Malavasi, N; Rossi, G; Venturelli, C | 1 |
Lanigan, LG; Martin, CK; Rosol, TJ; Thudi, NK; Toribio, RE; Werbeck, JL; Wolfe, TD | 1 |
Fujii, N; Ito, H; Nakabayashi, M; Ryoke, K; Shomori, K; Tamura, T | 1 |
Balakumaran, A; Ciuleanu, TE; García-Sáenz, JA; Henry, DH; Hirsh, V; Jacobs, I; Kanarev, V; Krzakowski, M; Lipton, L; Manegold, C; Mehta, ND; Pereira, JR; Prabhash, K; Rodriguez, G; Scagliotti, GV; Siena, S; Solal-Celigny, P; Wang, H; Woll, PJ | 1 |
Cao, JY; Chen, YQ; Cui, SX; Gao, HJ; Gao, J; Guo, CH; Liu, T; Mi, YJ; Qiu, GQ; Xie, JD; Yao, SP; Zhang, YY | 1 |
Dohdoh, M; Endo, Y; Kuroishi, T; Nagai, Y; Ohki, A; Oizumi, T; Sugawara, S; Tanaka, Y | 1 |
Langer, CJ | 1 |
McKenna, KE; Morris, TC; Ramadan, KM | 1 |
1 trial(s) available for zoledronic acid and Carcinoma, Epidermoid
Article | Year |
---|---|
Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Denosumab; Diphosphonates; Double-Blind Method; Female; Follow-Up Studies; Humans; Imidazoles; International Agencies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; RANK Ligand; Small Cell Lung Carcinoma; Survival Rate; Young Adult; Zoledronic Acid | 2012 |
17 other study(ies) available for zoledronic acid and Carcinoma, Epidermoid
Article | Year |
---|---|
Combining radiation therapy with zoledronate for the treatment of osteo-invasive feline oral squamous cell carcinoma.
Topics: Animals; Bone Density Conservation Agents; Carcinoma, Squamous Cell; Cat Diseases; Cats; Diphosphonates; Head and Neck Neoplasms; Mouth Neoplasms; Osteolysis; Quality of Life; Squamous Cell Carcinoma of Head and Neck; Zoledronic Acid | 2022 |
Zoledronate-responsive calcitriol-mediated hypercalcemia in a 5-year-old case with squamous cell carcinoma on the background of xeroderma pigmentosum.
Topics: Bone Density Conservation Agents; Calcitriol; Carcinoma, Squamous Cell; Child, Preschool; Humans; Hypercalcemia; Male; Paraneoplastic Syndromes; Prognosis; Xeroderma Pigmentosum; Zoledronic Acid | 2019 |
Potential chemotherapeutic effects of diosgenin, zoledronic acid and epigallocatechin-3-gallate on PE/CA-PJ15 oral squamous cancer cell line.
Topics: Apoptosis; Carcinoma, Squamous Cell; Catechin; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; Diosgenin; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Imidazoles; Mouth Neoplasms; Zoledronic Acid | 2017 |
Evaluation of a New Hydroxyapatite Nanoparticle as a Drug Delivery System to Oral Squamous Cell Carcinoma Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; Durapatite; Humans; MCF-7 Cells; Mouth Neoplasms; Nanoparticles; Zoledronic Acid | 2018 |
Human Vγ9Vδ2 T cells show potent antitumor activity against zoledronate-sensitized OSCC cell lines.
Topics: Apoptosis; Bone Density Conservation Agents; Carcinoma, Squamous Cell; Humans; Leukocytes, Mononuclear; Mouth Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; Tumor Cells, Cultured; Zoledronic Acid | 2018 |
Livedo reticularis heralding hypercalcaemia of malignancy.
Topics: Calcitonin; Carcinoma, Squamous Cell; Diphosphonates; Diuretics; Fluid Therapy; Follow-Up Studies; Humans; Hypercalcemia; Imidazoles; Livedo Reticularis; Male; Middle Aged; Monitoring, Physiologic; Mouth Neoplasms; Risk Assessment; Treatment Outcome; Zoledronic Acid | 2014 |
Laser-enhanced cytotoxicity of zoledronic acid and cisplatin on primary human fibroblasts and head and neck squamous cell carcinoma cell line UM-SCC-3.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Shape; Cell Survival; Cells, Cultured; Cisplatin; Coloring Agents; Diphosphonates; Fibroblasts; Head and Neck Neoplasms; Humans; Imidazoles; Indicators and Reagents; Lasers, Semiconductor; Low-Level Light Therapy; Photochemotherapy; Photosensitizing Agents; Tetrazolium Salts; Zoledronic Acid | 2014 |
Zoledronic acid and irradiation in oral squamous cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Cell Survival; Diphosphonates; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Evaluation, Preclinical; Humans; Imidazoles; Mouth Neoplasms; Radiotherapy Dosage; Time Factors; Zoledronic Acid | 2015 |
Rare association between penile squamous cell carcinoma and parathyroid related peptide (PTH-rP) secretion.
Topics: Bone Density Conservation Agents; Carcinoma, Squamous Cell; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Male; Middle Aged; Parathyroid Hormone; Pelvis; Penile Neoplasms; Rare Diseases; Tomography, X-Ray Computed; Zoledronic Acid | 2014 |
Extracellular Ca(2+)-dependent enhancement of cytocidal potency of zoledronic acid in human oral cancer cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Calcium; Calcium Chelating Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Cytochromes c; Diphosphonates; Dose-Response Relationship, Drug; Head and Neck Neoplasms; Humans; Imidazoles; MCF-7 Cells; Membrane Potential, Mitochondrial; Mitochondria; Mouth Neoplasms; Squamous Cell Carcinoma of Head and Neck; Zoledronic Acid | 2015 |
Pulmonary strongyloidiasis mimicking cancer symptoms: a case of hyperinfection in a patient with metastatic lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchoalveolar Lavage Fluid; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Dexamethasone; Diagnosis, Differential; Diphosphonates; Gemcitabine; Humans; Imidazoles; Immunocompromised Host; Lung Diseases, Parasitic; Lung Neoplasms; Male; Strongyloidiasis; Superinfection; Zoledronic Acid | 2008 |
Zoledronic acid reduces bone loss and tumor growth in an orthotopic xenograft model of osteolytic oral squamous cell carcinoma.
Topics: Acid Phosphatase; Animals; Bone Density Conservation Agents; Bone Resorption; Calcium; Carcinoma, Squamous Cell; Cats; Diphosphonates; Disease Models, Animal; Imidazoles; Isoenzymes; Luciferases; Male; Mice; Mice, Nude; Mouth Neoplasms; Osteoclasts; Osteolysis; Tartrate-Resistant Acid Phosphatase; Transplantation, Heterologous; X-Ray Microtomography; Zoledronic Acid | 2010 |
Zoledronic acid, a third-generation bisphosphonate, inhibits cellular growth and induces apoptosis in oral carcinoma cell lines.
Topics: Adenocarcinoma; Apoptosis; Blotting, Western; Bone Density Conservation Agents; Carcinoma, Squamous Cell; Caspases; Cell Cycle; Cell Proliferation; Diphosphonates; Flow Cytometry; Humans; Imidazoles; Immunoenzyme Techniques; Mouth Neoplasms; Salivary Gland Neoplasms; Tumor Cells, Cultured; Zoledronic Acid | 2011 |
Prognostic relevance and therapeutic implications of centromere protein F expression in patients with esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Chromosomal Proteins, Non-Histone; Cisplatin; Diphosphonates; Drug Screening Assays, Antitumor; Drug Synergism; Esophageal Neoplasms; Esophagus; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Male; Microfilament Proteins; Middle Aged; Neoplasm Staging; Prognosis; Proportional Hazards Models; Sex Factors; Survival Rate; Zoledronic Acid | 2013 |
In vitro cytotoxicity of zoledronate (nitrogen-containing bisphosphonate: NBP) and/or etidronate (non-NBP) in tumour cells and periodontal cells.
Topics: Adenocarcinoma; Annexin A5; Apoptosis; Bone Density Conservation Agents; Carcinoma, Squamous Cell; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Cells, Cultured; Coloring Agents; Dental Cementum; Diphosphonates; Endothelial Cells; Endothelium, Vascular; Etidronic Acid; Fibroblasts; Fluorescein-5-isothiocyanate; Fluorescent Dyes; Gingiva; Humans; Imidazoles; Leukemia, Monocytic, Acute; Mesenchymal Stem Cells; Periodontal Ligament; Propidium; Tetrazolium Salts; Umbilical Veins; Zoledronic Acid | 2013 |
Role of zoledronic acid in the setting of bone metastases from non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Squamous Cell; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Lung Neoplasms; Middle Aged; Osteoarthropathy, Secondary Hypertrophic; Zoledronic Acid | 2005 |
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Clarithromycin; Dexamethasone; Diphosphonates; Glomerulonephritis; Humans; Idarubicin; Imidazoles; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Nephrotic Syndrome; Pamidronate; Protein Synthesis Inhibitors; Pyrazines; Skin Neoplasms; Thalidomide; Zoledronic Acid | 2006 |